Skip to main content

Author: Customer Service

Festi hf.: Transactions in relation to a share repurchase programme – week 32

In week 32 2026, Festi purchased in total 265,000 own shares for total amount of 81,677,500 ISK as follows:Week Date Time Purchased shares Share price Purchase price  32 4.8.2026 10:49:24 40.000 308,5 12.340.00032 5.8.2026 11:02:15 59.595 308,5 18.385.05832 5.8.2026 11:11:44 15.405 308,5 4.752.44332 6.8.2026 12:01:14 75.000 308,5 23.137.50032 7.8.2026 11:20:19 75.000 307,5 23.062.500       265.000   81.677.500                         The execution of the buyback program is in accordance with the Act on Public Limited Companies No 2/1995, Article 5 of the Regulation of the European Parliament and of the Council No. 596/2014, on market abuse, the Commission Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before these purchases, Festi held 4,678,864 own shares, corresponding...

Continue reading

Niu Technologies Announces Unaudited Second Quarter 2026 Financial Results

— Second Quarter Revenues of RMB 1,440.4 million, up 14.7% year over year — Second Quarter Net Loss of RMB 102.2 million, compared with Net Income of RMB 5.9 million in the same period of 2025 BEIJING, Aug. 10, 2026 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or the “Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced its unaudited financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial HighlightsRevenues were RMB 1,440.4 million, an increase of 14.7% year over year Gross margin was 16.0%, compared with 20.1% in the second quarter of 2025 Net loss was RMB 102.2 million, compared with net income of RMB 5.9 million in the second quarter of 2025 Adjusted net loss (non-GAAP)1 was RMB 98.2 million, compared with adjusted net income...

Continue reading

Portuguese National Security Agency Selects BIO-key and Visualforma to Strengthen Identity Security

Contract reinforces the protection of one of Portugal’s highest-security government environments with advanced Identity and Access Management and biometric authentication FARO, Portugal and HOLMDEL, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) — BIO-key International, Inc. (Nasdaq: BKYI), a global innovator in Identity and Access Management (IAM) and biometric authentication solutions, today announced that, together with its strategic Portuguese partner Visualforma, it has been awarded a new contract to strengthen digital identity security for a Portuguese national security agency. The award is a significant expansion of BIO-key’s and Visualforma’s long-standing collaboration within the Portuguese public sector. Following successful deployments across government organizations and municipalities, it now extends into one of the country’s...

Continue reading

Storebrand Europe Index – announcement of prospectus

                                                                                                          Lysaker, 10 August 2026 Storebrand hereby announces theProspectus with Articles of Association Appendix to the Prospectus (“tillæg” relevant to Danish investors)for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq Copenhagen and is scheduled for trading on Wednesday 12 August 2026. At end of business on 7 August 2026 the fund had the following diversification characteristics for the shareclass to be listed, Storebrand Europe Index A5 – ISIN NO0013711408:Total net assets (“Formue”):                                    DKK 135.524,10 Outstanding units (“Circulerende andele”):           1.218,8362 Investors (“Unikke investorer”):                              11The Storebrand...

Continue reading

Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities

Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities COPENHAGEN, Denmark, August 10 – Novonesis has signed an agreement with the intent to acquire MicroBioGen, an Australian biotechnology company with leading scientific expertise in yeast strains for industrial applications, particularly in bioethanol. The acquisition builds on Novonesis’ 2013 investment in MicroBioGen and its current 23% stake, further strengthening a decade-long collaboration in advanced yeast solutions for bioethanol production.Ester Baiget, CEO: “This acquisition marks an additional step in our 2030 strategy. It strengthens our yeast capabilities, strengthens our R&D capabilities, and reflects our disciplined investment focus to drive growth.”Building on deep scientific expertise As a pure-play biology company, Novonesis...

Continue reading

Global Power Solutions signs non-binding LOI with SolarZone Energy for potential deployment of modular power systems

Vancouver, BC, Canada, Aug. 10, 2026 (GLOBE NEWSWIRE) — Global Power Solutions Corp. (TSX Venture Exchange: PWER; Frankfurt Stock Exchanges: NJA) (“Global Power” or the “Company”) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Solar Zone LLC, operating as SolarZone Energy (“SolarZone”), to evaluate the potential deployment of Global Power’s proposed 5 megawatt (“MW”) modular decentralized power systems across multiple sites in the United States. The LOI establishes a preliminary framework for Global Power to be evaluated as a prospective technology and equipment vendor for SolarZone’s proposed clean energy infrastructure build-out. All deployments contemplated under the LOI are expressly subject to the successful completion, commercial testing and performance validation of the initial...

Continue reading

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a private translational neuroscience R&D company, today announced that Oculis and Accure have entered into an asset purchase agreement whereby, upon closing, Oculis will acquire all of Accure’s worldwide development and commercial rights to Privosegtor. This acquisition will result in the termination of Oculis’ existing license agreement with Accure, including associated milestone payments and royalties for each successful indication. This strategic transaction would enable Oculis to better harness Privosegtor’s...

Continue reading

46/2026・Trifork Group: Weekly report on share buyback

Schindellegi, Switzerland – 10 August 2026 Trifork Group AGCompany announcement no. 46/2026 Weekly report on share buyback On 27 February 2026, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 March 2026 up to and including no later than 31 December 2026. For details, please see company announcement no. 15 of 27 February 2026. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 75 million (approximately EUR 10 million). Under the program, the following transactions have been made:Date                                 Number of shares       Average purchase price (DKK)       Transaction value...

Continue reading

PRU FY26 Results Investor Webinar

Perth, Western Australia, Aug. 10, 2026 (GLOBE NEWSWIRE) — FY26 RESULTS INVESTOR WEBINAR / CALL Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its FY26 Results, which are anticipated for release around 8:30am AEST on Wednesday, 26 August 2026. CALL DETAILSAustralia: Wednesday 26 August 2026 Perth – 7:00am Sydney/Melbourne – 9:00am Canada: Tuesday 25 August 2026 Vancouver – 4:00pm Toronto – 7:00pm UK: Wednesday 26 August 2026 London – 12:00 midnightRegister for the investor webinar at the link below: https://us02web.zoom.us/webinar/register/WN_Xej7zujzRbCdLDKmJBhl-g After registering, you will receive a confirmation email containing information about joining the webinar. To join the webinar via telephone, please use one of the following numbers and enter the Webinar ID:...

Continue reading

Share Buy-back Programme – Transactions Week 32

On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital. Gabriel Holding A/S held 55,109 treasury shares at the start of the share buyback programme. The buy-back is executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulation. The buy-back is carried out on Nasdaq Copenhagen at market price and in accordance with the authorization granted by the general meeting, Nasdaq Copenhagen’s rules for issuers, as well as Gabriel Holding A/S’ internal rules on insider matters...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.